Dihexa

Dihexa is a small peptide mimetic derived from the angiotensin IV sequence. It binds the AT4 receptor, which was identified as insulin-regulated aminopeptidase (IRAP), and it potentiates hepatocyte growth factor (HGF) signaling at the c-Met receptor tyrosine kinase. The downstream effect in rodent hippocampal tissue is increased dendritic spine density and new synapse assembly, a phenomenon called synaptogenesis. The mechanism is biologically coherent and links an angiotensin-system receptor to a growth-factor pathway that also appears in tumor biology. This dual identity (cognitive enhancer and oncogenic pathway activator) is the central tension of the compound.

Benoist 2011 reported that aged rats with impaired Morris water maze performance showed restored spatial memory after daily dihexa administration, framed as an angiotensin IV memory-restoration signal. McCoy 2013 reported that dihexa applied to rat hippocampal slices produced a measurable increase in dendritic spine density and functional synapse number, which the authors called synaptogenic activity in the picomolar range. Both papers came out of the Harding and Wright labs at Washington State University. Three foundational papers from that group, including related dihexa work, were later retracted for data fabrication. The rodent findings are directionally interesting but the underlying dataset is now compromised and should be read with caution.

The original WSU program pivoted into a structurally distinct clinical candidate called fosgonimeton (ATH-1017) through Athira Pharma. Fosgonimeton went through IND filing, Phase 1, and is currently in Phase 2 / 3 for Alzheimer's disease. Dihexa itself was never developed as a clinical candidate by the originating lab or any commercial sponsor. The founding papers were partially retracted for data fabrication, which removed the scientific and regulatory path for dihexa specifically. No IND on public file, no ClinicalTrials.gov entry, no commercial program advancing it. Human data on dihexa may never arrive through a formal trial pathway.

Gray-market community reports describe vivid subjective cognitive acuity within 1-3 days, sharper verbal recall, faster pattern recognition, and near-universal vivid dreams while on-cycle. Some users report headaches, anxiety, and overstimulation as off-target side effects. These reports are uniformly subjective and anecdotal. There is zero objective data (no Cogstate, no CANTAB, no biomarker, no structural imaging) in any gray-market or formal setting. The user base is small, self-selected, and operating without a control group. Subjective acuity is exactly the class of signal most vulnerable to placebo and expectation effects. Nothing about the community report base constitutes evidence of efficacy in a scientific sense.

The concern is serious and biologically grounded. c-Met is a validated oncogenic receptor tyrosine kinase, and multiple FDA-approved cancer drugs (capmatinib, tepotinib, crizotinib) were designed specifically to block c-Met signaling in lung cancer and other tumors. HGF / c-Met activation is a documented driver of tumor growth and metastasis across several cancer types (Comoglio 2008). Chronic pharmacologic activation of this pathway in a healthy user is the opposite of what oncology is trying to achieve. No carcinogenicity study on dihexa. No human long-term safety data. The risk is theoretical only because exposure has been small and short, not because biology suggests safety.

Dihexa is sold by a small number of gray-market research-chemical and peptide vendors, almost always labeled "for research use only, not for human consumption." These vendors operate outside cGMP pharmaceutical manufacturing. Independent HPLC and mass-spec verification of identity and purity is rare, and lot-release testing is essentially nonexistent. A product labeled dihexa may contain the intended peptide, a degradation product, a different compound entirely, or contaminants. There is no recall mechanism, no adverse-event reporting, no FDA consumer protection. The supply chain risk stacks on top of the compound-level risk.

Personal or family history of any cancer is a hard contraindication given the c-Met oncogenic pathway and the absence of carcinogenicity data. Pregnancy, lactation, and pediatric use are absolute contraindications because no safety data exists in those populations. Anyone with cardiovascular disease should avoid it because HGF and c-Met play roles in cardiac remodeling that are uncharacterized in healthy adults. Anyone on prescription medications should avoid it because there is zero drug-interaction data. Anyone who cannot independently verify product identity through third-party testing should not use a gray-market product in this risk class.

Dihexa is not a scheduled controlled substance, so simple personal possession is not a drug-scheduling offense in the US. However, sale and distribution for human consumption are illegal under the Federal Food, Drug, and Cosmetic Act (FDCA), which is why every vendor labels the product "for research use only, not for human consumption." That label does not create a safe harbor for buyers who intend to self-administer. In practice, individual buyers are not prosecuted, but the compound is squarely in a legal gray area. There is no FDA-approved human use, no legal marketing channel, no labeling guarantee, and no regulatory consumer protection if something goes wrong.